open-label dose-rang trial AL patient persist lymphadenopathi aids-rel complex AL lipid mixtur vitro activ human immunodefici viru hiv cell membran virion cholesterol deplet multicent open-label dose-rang trial forti men persist lymphadenopathi aids-rel complex dose week toxic diseas progress immunolog virolog serum lipid profil compound broad rang dose advers reaction gastrointestin tract mild sever self-limit durat weight gain treatment week cessat therapi diseas progress short-term studi indic immunorestor antivir effect AL t-lymphocyt subset quantit hiv cultur patient hiv antigenem entri posit antigen level treatment consequ therapi signific increas serum lipid elev triglycerid total cholesterol level conclus experi group hiv-infect patient dose AL support use compound antiretrovir agent 